Medically reviewed by Soma Mandal, MD With petechiae, you may notice tiny red, purple, or brown spots that occur when ...

PhaseBio’s Brilinta reversal drug has scored a midstage win without any adverse events or blood clot issues, layering on the data to support the therapy that’s already pushing through phase 3.

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s BRILINTA ® (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with ...

A few months ago, AstraZeneca’s Brilinta added a new U.S. indication to reduce the chance of a first heart attack or stroke in certain high-risk patients. Now, the blood thinner has won a green light ...

AstraZeneca PLC AZN announced that the FDA has accepted the supplemental New Drug Application (sNDA) for its blood thinner medicine Brilinta (ticagrelor). The company is seeking label expansion of ...

New Brilinta indication expands treatment to high-risk coronary patients without a history of stroke or heart attack AstraZeneca’s Brilinta (ticagrelor) has been cleared by US regulators to cut the ...

AstraZeneca has put a lot of resources behind its aging blood thinner Brilinta, hoping to keep the anticoagulant's place in doctors' minds fresh for years to come. With a suite of new data and ...

Consistent results were also observed in patients undergoing complex percutaneous coronary intervention Results from two subgroup analyses of the Phase IV independent TWILIGHT trial funded by ...

Results from two subgroup analyses of the Phase IV independent TWILIGHT trial funded by AstraZeneca showed Brilinta (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding over 12 ...

WILMINGTON, Del.--(BUSINESS WIRE)--High-level results from the Phase III THALES trial showed AstraZeneca’s BRILINTA (ticagrelor) 90 mg used twice daily and taken with aspirin for 30 days, reached a ...